Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

Nivolumab plus Brentuximab vedotin +/- bendamustine combination therapy: a safe and effective treatment in pediatric recurrent and refractory classical Hodgkin lymphoma

IntroductionClassical Hodgkin lymphoma (cHL) is the most common pediatric lymphoma. Approximately 10% of patients develop refractory or recurrent disease. These patients are treated with intensive chemotherapy followed by consolidation with radiotherapy or high-dose chemotherapy and autologous stem...

Full description

Bibliographic Details
Main Authors: Patrick Greve, Auke Beishuizen, Melanie Hagleitner, Jan Loeffen, Margreet Veening, Marianne Boes, Victor Peperzak, Claudius Diez, Friederike Meyer-Wentrup
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-07-01
Series:Frontiers in Immunology
Subjects:
oncology
recurrent/refractory classical Hodgkin lymphoma
checkpoint inhibition
combination immunotherapy
targeted therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1229558/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1229558/full

Similar Items